Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin

RE-COVER, 2009 - dabigatran vs vitamin K antagonists

Romera, 2009 - Tinzaparin vs acenocoumarol

González-Fajardo, 2008 - Enoxaparin vs coumarin

Botticelli DVT, 2008 - apixaban vs heparin/VKA

Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA

VanGogh DVT, 2007 - idraparinux vs heparin/VKA

VanGogh PE, 2007 - idraparinux vs heparin/VKA

Daskalopoulos, 2005 - LMWH at home vs UFH in hospital

Fiessinger , 2005 - ximelagatran vs vitamin K antagonists

Chong, 2005 - LMWH at home vs UFH in hospital

Kearon, 2004 - 4 months vs 3 months

Ramacciotti, 2004 - LMWH at home vs UFH in hospital

MATISSE, 2004 - fondaparinux vs enoxaparin

Lee, 2003 - Dalteparin vs warfarin

Agnelli, 2003 - 6-12 months vs 3 months

Kakkar, 2003 - Bemiparin vs warfarin

Deitcher, 2003 - Enoxaparin vs warfarin

MATISSE PE, 2003 - fondaparinux vs heparin/VKA

Hull, 2002 - Tinzaparin vs warfarin

Meyer, 2002 - Enoxaparin vs warfarin

Agnelli, 2001 - 12 months vs 3 months

Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH

Lopez-Beret, 2001 - Nadroparin vs acenocoumarol

Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin



See also:

  • All venous thrombosis clinical trials
  •  

    Pinede study, 2001

    Treatments

    Studied treatment Long course of therapy (6 months for proximal DVT and/or PE; 12 weeks for calf DVT) by fluindione adjusted for INR range of 2.0 to 3.0
    Control treatment Short oral anticoagulant course (3 months for proximal DVT and/or PE; 6 weeks for isolated calf DVT) by fluindione adjusted for INR range of 2.0 to 3.0
    Remarks randomization at the end of heparin therapy

    Patients

    Inclusion criteria symptomatic thrombus below popliteal vein or proximal deep vein thrombosis and/or pulmonary embolism confirmed by positive Doppler ultrasonography or venography
    Exclusion criteria Pregnancy, breast feeding, previous venous thromboembolism, vena cava filter implantation, surgical thrombectomy, free-floating thrombus in the inferior vena cava lumen, deep vein thrombosis or pulmonary embolism whose diagnosis did not fulfill the predefined criteria, evolutionary cancer or malignant hematological disease, known biological thrombophilia, severe pulmonary embolism, pulmonary embolism treated by thrombolysis, myocardiopathy or other diseases justifying prolonged anticoagulation therapy, and liver insufficiency
    Baseline characteristics
    time of randomization after heparin therapy 

    Method and design

    Randomized effectives NA / NA (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 15 months after randomizationŰ
    Lost to follow-up n=22
    Number of centre 94
    Geographic area France
    Primary endpoint Recurrent VTE


    Results

    No results available for this trial - no clinical endpoint reported



    Reference(s)

    Trials register # NA
    • Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis.. Circulation 2001;103:2453-60
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend